Shares of GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) have been given an average recommendation of “Hold” by the ten analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $67.7778.
Several equities research analysts have issued reports on the stock. The Goldman Sachs Group began coverage on shares of GRAIL in a research note on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Robert W. Baird set a $70.00 price target on GRAIL in a research report on Wednesday, May 6th. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th.
View Our Latest Research Report on GRAIL
Insider Buying and Selling
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada raised its stake in shares of GRAIL by 17.7% in the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after buying an additional 13,264 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after purchasing an additional 623 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after purchasing an additional 1,401 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of GRAIL by 37.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock worth $2,362,000 after purchasing an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of GRAIL by 115.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock worth $4,090,000 after purchasing an additional 42,675 shares in the last quarter.
GRAIL Stock Up 4.3%
Shares of GRAL opened at $73.96 on Thursday. The firm has a market cap of $3.30 billion, a PE ratio of -7.59 and a beta of 3.24. The company’s fifty day moving average is $68.26 and its two-hundred day moving average is $64.38. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84.
GRAIL (NASDAQ:GRAL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, equities research analysts anticipate that GRAIL will post -10.41 earnings per share for the current year.
GRAIL Company Profile
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.
Featured Stories
- Five stocks we like better than GRAIL
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
